Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-01-10, Stock:ABBV, The news for the past five days is as follows:
2019-01-03: NEWS1: 3 Biopharma Stocks to Buy for Their Robust Dividend Yields.NEWS2: 3 Biopharma Stocks to Buy for Their Robust Dividend Yields.NEWS3: Bristol-Myers Angles To Become Mega-Pharma With $74 Billion Celgene Bid.NEWS4: 3 Biopharma Stocks to Buy for Their Robust Dividend Yields.NEWS5: Will Pfizer's (PFE) Stock Keep Up the Momentum in 2019?.NEWS6: Will Pfizer's (PFE) Stock Keep Up the Momentum in 2019?.NEWS7: Will Pfizer's (PFE) Stock Keep Up the Momentum in 2019?.NEWS8: AbbVie and Tizona Therapeutics Announce Strategic Collaboration to Develop First-in-Class Immunotherapy for Cancer Targeting CD39.NEWS9: AbbVie Falls 3%.NEWS10: 3 Big Stock Charts for Thursday: Medtronic, Facebook and eBay.NEWS11: AbbVie to Host Fourth-Quarter and Full-Year 2018 Earnings Conference Call.
2019-01-04: NEWS1: Cramer's lightning round: 'Do some trimming' in Qualcomm if the stock rallies.NEWS2: AbbVie (ABBV) Inks Immunotherapy Deal with Private Biotech.NEWS3: Which Biopharma Stocks Are Looking To Score Big In Cannabis Medicine?.NEWS4: Pharma Stock Roundup: BMY to Buy CELG for $74B, MRK Gets Rights to NASH Candidate.NEWS5: Pharma Stock Roundup: BMY to Buy CELG for $74B, MRK Gets Rights to NASH Candidate.NEWS6: Pharma Stock Roundup: BMY to Buy CELG for $74B, MRK Gets Rights to NASH Candidate.NEWS7: Pfizer Begins Pivotal Study on Alopecia Areata Candidate.NEWS8: Pfizer Begins Pivotal Study on Alopecia Areata Candidate.NEWS9: AbbVie Rises 3%.NEWS10: Pfizer Begins Pivotal Study on Alopecia Areata Candidate.
2019-01-07: NEWS1: AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know.NEWS2: Peninsula Alzheimer's fighter hunts $150 million IPO.NEWS3: Neurocrine Gives Ingrezza Sales View, Updates on Pipeline.NEWS4: Neurocrine Gives Ingrezza Sales View, Updates on Pipeline.NEWS5: Neurocrine Gives Ingrezza Sales View, Updates on Pipeline.NEWS6: Neurocrine Biosciences Is a Pharma Stock to Watch.NEWS7: Neurocrine Biosciences Is a Pharma Stock to Watch.NEWS8: Notable ETF Inflow Detected - SDY, T, O, ABBV.NEWS9: Notable ETF Inflow Detected - SDY, T, O, ABBV.NEWS10: As Patent Expirations Loom, the Clock Is Ticking on AbbVie Stock.NEWS11: Gilead (GILD) Collaborates With Yuhan for NASH Candidates.NEWS12: Gilead (GILD) Collaborates With Yuhan for NASH Candidates.NEWS13: Gilead (GILD) Collaborates With Yuhan for NASH Candidates.NEWS14: Jim Cramer Gives His Opinion On Ciena, Momo, Qualcomm And More.NEWS15: Neurocrine Biosciences Is a Pharma Stock to Watch.NEWS16: Today's Research Reports on Trending Tickers: AbbVie and Allergan.NEWS17: The Zacks Analyst Blog Highlights: Bristol-Myers, Celgene, Merck, Pfizer and AbbVie.NEWS18: The Zacks Analyst Blog Highlights: Bristol-Myers, Celgene, Merck, Pfizer and AbbVie.NEWS19: The Zacks Analyst Blog Highlights: Bristol-Myers, Celgene, Merck, Pfizer and AbbVie.NEWS20: 3 Bargain Stocks You Can Buy Right Now.NEWS21: 3 Bargain Stocks You Can Buy Right Now.
2019-01-08: NEWS1: Top Analyst Reports for Visa, Coca-Cola & AbbVie.NEWS2: AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know.NEWS3: AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know.
2019-01-09: NEWS1: AbbVie Falls 3%.NEWS2: Novartis' Crizanlizumab Gets Breakthrough Therapy Status.NEWS3: Novartis' Crizanlizumab Gets Breakthrough Therapy Status.NEWS4: The Zacks Analyst Blog Highlights: Visa, Coca-Cola, AbbVie, Johnson & Johnson and Duke Energy.NEWS5: The Zacks Analyst Blog Highlights: Visa, Coca-Cola, AbbVie, Johnson & Johnson and Duke Energy.NEWS6: Is AbbVie (ABBV) a Great Value Stock Right Now?.NEWS7: Is AbbVie (ABBV) a Great Value Stock Right Now?.NEWS8: Is AbbVie (ABBV) a Great Value Stock Right Now?.NEWS9: The Zacks Analyst Blog Highlights: Visa, Coca-Cola, AbbVie, Johnson & Johnson and Duke Energy.NEWS10: Novartis' Crizanlizumab Gets Breakthrough Therapy Status.NEWS11: See what the IHS Markit Score report has to say about AbbVie Inc..NEWS12: Inside look: LNG bunker that puts Jaxport on world map.NEWS13: Top Picks 2019- AbbVie Inc. ABBV.

Answer: Rise